U.S. markets closed

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
59.10+0.22 (+0.37%)
At close: 4:00PM EDT

59.10 0.00 (0.00%)
After hours: 5:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close58.88
Bid57.00 x 1200
Ask59.25 x 800
Day's Range57.97 - 60.49
52 Week Range19.51 - 73.72
Avg. Volume1,511,715
Market Cap6.045B
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-0.25
Earnings DateNov 23, 2020 - Nov 27, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est66.64
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-33% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Arrowhead Pharmaceuticals Stock Jumped Today
    Motley Fool

    Why Arrowhead Pharmaceuticals Stock Jumped Today

    Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) rose sharply on Thursday and closed today's trading session up 9.9% after climbing by as much as 14.4%. The drugmaker did not report any news, but biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX) released an update regarding one of its pipeline candidates, and the update bodes well for Arrowhead and its shareholders. On Wednesday evening, Vertex announced it would discontinue the development of VX-814, a potential treatment for alpha-1 antitrypsin deficiency (AATD), a genetic condition that can cause lung or liver disease.

  • Vertex Tumbles As It Stops Testing On Protein Deficiency Treatment
    Investor's Business Daily

    Vertex Tumbles As It Stops Testing On Protein Deficiency Treatment

    Shares of Vertex plunged after hours Wednesday after the company announced it planned to stop testing on a drug designed to treat protein deficiencies. VRTX stock fell by double digits.

  • Benzinga

    Looking Into Arrowhead Pharmaceuticals's Return On Capital Employed

    Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q3 sales of $27.38 million. Earnings fell to a loss of $15.95 million, resulting in a 28.3% decrease from last quarter. Arrowhead Pharmaceuticals collected $23.53 million in revenue during Q2, but reported earnings showed a $22.24 million loss.What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Arrowhead Pharmaceuticals posted an ROCE of -0.03%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on ARWRROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Arrowhead Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In Arrowhead Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q3 Earnings Recap Arrowhead Pharmaceuticals reported Q3 earnings per share at $-0.13/share, which did not meet analyst predictions of $-0.12/share.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * 12 Healthcare Stocks Moving In Thursday's Pre-Market Session * Looking Into Arrowhead Pharmaceuticals's Return On Capital Employed(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.